Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract

Pycha, Armin; Grbovic, M; Posch, Bernd; Schnack, Beate; Haitel, Andrea; Heinz-Peer, Gertraud; Zielinski, Christoph; Marberger, Michael

doi:10.1016/s0090-4295(98)00543-3

Cited by 39 publications

(9 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 72% response rate and median survival Ͼ 13 months were reported. 11 Small et al reported the Southwest Oncology Group (SWOG) trial of paclitaxel 200 mg/m 2 plus carboplatin AUC 5 every 21 days. In this trial, a response rate of only 21% was seen, with median survival of 9 months.…”

Section: Discussionmentioning

confidence: 99%

Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896)

Vaughn

Manola

Dreicer

et al. 2002

Cancer

View full text Add to dashboard Cite

BACKGROUNDChemotherapy options for the patients with advanced urothelial carcinoma and renal dysfunction are limited. The authors performed a Phase II trial of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction.METHODSForty‐two patients were accrued; 37 eligible patients were treated. Patients received paclitaxel 225 mg/m2 over three hours followed by carboplatin targeted area under the concentration‐time curve = 6 mg/mL · minute every three weeks for up to six cycles.RESULTSThe median number of cycles received was four (range, one to six). The objective response rate was 24.3% (95% confidence interval, 11.9–41.7%). The median progression free survival was 3 months and the median overall survival was 7.1 months. The number of poor prognostic risk factors (Eastern Cooperative Oncology Group performance status > 1 or lung, liver, or bone metastases) significantly predicted for survival. The most common ≥ 1 Grade 3 toxicities included granulocytopenia (60%) and neurotoxicity (35%).CONCLUSIONSPaclitaxel/carboplatin is a chemotherapy option for patients with advanced urothelial carcinoma and renal dysfunction. Future trials in chemotherapy development for this patient population are warranted. Cancer 2002;95:1022–7. © 2002 American Cancer Society.DOI 10.1002/cncr.10782

show abstract

Section: Discussionmentioning

confidence: 99%

Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896)

Vaughn

Manola

Dreicer

et al. 2002

Cancer

View full text Add to dashboard Cite

show abstract

“…Several second-line regimens have been described for advanced UC, such as paclitaxel/carboplatin (Pca) [4], paclitaxel/ifosfamide [5], paclitaxel/cisplatin/methotrexate [6], and paclitaxel/gemcitabine [7]. In our institution, the Pca regimen has been adopted as second-line chemotherapy after M-VAC.…”

Section: Introductionmentioning

confidence: 99%

Third-line gemcitabine monotherapy for platinum-resistant advanced urothelial cancer

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Several phase II trials have evaluated the combination of various doses (150-225 mg/m 2 ) of paclitaxel with carboplatin (AUC 5-6) reporting overall RRs of 14-65%, with CRs in 0-40% [28][29][30][31][32]. This regimen is well tolerated with predominantly mild hematologic and neurologic toxicities.…”

Section: Doublet Chemotherapymentioning

confidence: 99%

The evolving role of chemotherapy in advanced urothelial cancer

Calabrò

Sternberg²

2007

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

Randomized trials have demonstrated that cisplatin-based combination chemotherapy can be considered the standard treatment for fit patients with metastatic urothelial cancer. However, several newer regimens have failed to demonstrate superiority in terms of overall survival when compared to classic methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC). The addition of a third agent to doublet combinations is still uncertain. New drugs including pemetrexed and vinflunine are now being studied for second-line therapy. Progress in the understanding of the molecular biology of bladder cancer and identification of new targeted therapies will provide new opportunities. In addition to newer drug combinations, tailoring of chemotherapy on the basis of molecular characteristics to predict chemosensitivity will provide new challenges.

show abstract

Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract

Cited by 39 publications

References 25 publications

Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896)

Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896)

Third-line gemcitabine monotherapy for platinum-resistant advanced urothelial cancer

The evolving role of chemotherapy in advanced urothelial cancer

Contact Info

Product

Resources

About